1-866-598-7166

A Study of Autogene Cevumeran (RO7198457) Alone or in Combination with Atezolizumab in Patients with Advanced Solid Tumours

Trial ID: NCT03289962
Kidney Cancer Type: Clear cell or sarcomatoid components


Background:

This study involves a number of different medications.

The first is called “Autogene Cevumeran” (RO7198457), which is an experimental cancer therapy similar to a vaccine. This drug works by “teaching” your immune system how to fight off cancer cells using an injection of harmless tumour material. Since this treatment is not yet approved by Health Canada, it currently has the placeholder name RO7198457.

The other drug in this study is called Atezolizumab (Tecentriq®), which is a Health Canada-approved immunotherapy treatment for kidney cancer. Atezolizumab works by reactivating the body’s own immune response to target and destroy cancer cells.


The Trial:

This study will investigate the safety and effectiveness of RO7198457 given either by itself, or in combination with Atezolizumab. You will be randomly assigned to one of these two groups.

Different doses of RO7198457 will be used to determine the optimal dosage.


Basic Eligibility:

  • Clear cell kidney cancer (incl. sarcomatoid features)
  • Cancer has spread or cannot be removed by surgery
  • Must have received at least one other treatment for kidney cancer
  • No previous treatment with immunotherapy

Additional eligibility criteria will apply. Please speak to your doctor.

 

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreOttawa Hospital Cancer Centre Principal Investigator LocationOttawa, ON Trial StatusRecruiting
Hospital / Cancer CentrePrincess Margaret Cancer Centre Principal InvestigatorDr. Lillian Siu LocationToronto, ON Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!